Four Critical Aspects of Clinical Development, Manufacturing, and Analysis for Biologics CDMO
Scorpius BioManufacturing discusses the importance of selecting the right CDMO for your next clinical biologic campaign. They cover what attributes are needed through evaluating analytical integration as well as new technologies to look for that will mitigate risk and speed your drug’s manufacturing timelines,
Related Content
New Strategies for a Better Glycosylation Profile
January 22nd 2025Article
Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
